Prof Anne Rogiers and Prof Bart Neyns discuss the key results of the PRESERV-MEL study, a real-world study evaluating adjuvant nivolumab in patients with resected melanoma in Belgium and Luxembourg
Ariez Publishing
Prof Anne Rogiers and Prof Bart Neyns discuss the key results of the PRESERV-MEL study, a real-world study evaluating adjuvant nivolumab in patients with resected melanoma in Belgium and Luxembourg
00:00 / 11:03